Association of MICA and AT1R antibodies with antibody-mediated rejection and cardiac allograft vasculopathy in a pediatric heart transplant recipient.

Autor: Chou-Wu E; Immunogenetics/HLA Laboratory, Bloodworks Northwest, Seattle, WA, United States. Electronic address: echou@bloodworksnw.org., Kemna M; Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, United States., Ross S; Immunogenetics/HLA Laboratory, Bloodworks Northwest, Seattle, WA, United States., Youngs D; Immunogenetics/HLA Laboratory, Bloodworks Northwest, Seattle, WA, United States., Law Y; Division of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, United States., Gimferrer I; Immunogenetics/HLA Laboratory, Bloodworks Northwest, Seattle, WA, United States.
Jazyk: angličtina
Zdroj: Transplant immunology [Transpl Immunol] 2023 Jun; Vol. 78, pp. 101811. Date of Electronic Publication: 2023 Mar 06.
DOI: 10.1016/j.trim.2023.101811
Abstrakt: Background: Recipient antibodies against mismatched donor-specific human leukocyte antigens (HLA) are known to be associated with antibody-mediated rejection (AMR), posing increased risks of cardiac allograft vasculopathy (CAV), graft dysfunction, and graft loss after heart transplant (HTx). However, the impact of non-HLA antibodies on HTx outcome is not yet well defined.
Case Description: Here we report a case of a pediatric patient, who was retransplanted after developing CAV in his first heart allograft. Five years post 2nd HTx, the patient presented with graft dysfunction and mild rejection (ACR 1R, AMR 1H, C4d Neg) in the cardiac biopsy in the absence of HLA donor-specific antibodies (DSAs). We detected strong antibodies against non-HLA antigens, including angiotensin II receptor type 1 (AT1R) and donor-specific MHC class I chain-related gene A (MICA), in the patient's serum that were implicated in the AMR and accelerated CAV of his second allograft, and likely played a role in the loss of his first allograft as well.
Conclusion: This case report underscores the clinical relevance of non-HLA antibodies in heart transplantation and highlights the value of incorporating these tests in the immunological risk assessment and post-transplant monitoring of HTx recipients.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE